How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

987 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet. Full Text available with Trip Pro

Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet. There have been no studies of dual administration of sublingual immunotherapy (SLIT) tablets for perennial and seasonal allergic rhinitis. This trial (JapicCTI-184014) was conducted to investigate the safety profile and immunological response during dual therapy with SQ house dust mite (HDM) and Japanese cedar pollen (JCP) SLIT tablets.This was a multicenter

2019 Allergology international : official journal of the Japanese Society of Allergology Controlled trial quality: uncertain

22. Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: Evaluation of a phase II/III trial over three pollen dispersal seasons. Full Text available with Trip Pro

Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: Evaluation of a phase II/III trial over three pollen dispersal seasons. We conducted a randomized, placebo-controlled, double-blind clinical trial to investigate the optimal dose and long-term efficacy and safety of Japanese cedar (JC) pollen tablets for SLIT (JapicCTI-142579). Here, we report details of the effects of the JC pollen SLIT tablet on rhinitis and conjunctivitis symptoms over three pollen

2019 Allergology international : official journal of the Japanese Society of Allergology Controlled trial quality: predicted high

23. Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study. Full Text available with Trip Pro

Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study. Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of Dermatophagoides Farinae (D. farinae Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited (...) and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual D. farinae Drops groups (high-dose, medium-dose and low-dose), respectively. Statistical analysis was performed in three groups: Full Analysis Set, Per Protocol Set and Safety Set. 48 cases have withdrawn from the study before the end of study. As primary outcomes, significant decreases in scoring atopic dermatitis and total medication score

2019 Artificial Cells, Nanomedicine, and Biotechnology Controlled trial quality: predicted high

24. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children. (Abstract)

Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children. Immunomodulatory effects of sublingual immunotherapy on systemic and mucosal mediators in allergic children are largely unexplored. The aim of this study was to investigate allergy related cytokine and chemokine levels, as well as IgA responses upon a three-year treatment with timothy grass pollen sublingual immunotherapy in children with allergic rhinoconjunctivitis.From children included (...) of allergic rhinitis in terms of both severity and visual analogue scale scores. However, no consistent correlations were found between the clinical outcomes and immunological parameters.Phleum pratense sublingual immunotherapy in grass pollen allergic children modulates the immune response in the oral mucosa as well as systemically, by increasing Th1-responses, decreasing Th2-responses and inducing immunoregulatory responses - all signs of tolerance induction. This article is protected by copyright. All

2019 Pediatric Allergy and Immunology

25. Acupuncture as an add-on therapy to sublingual allergen-specific immunotherapy for patients with allergic rhinitis. Full Text available with Trip Pro

Acupuncture as an add-on therapy to sublingual allergen-specific immunotherapy for patients with allergic rhinitis. This study retrospectively analyzed the effectiveness of acupuncture as add-on therapy (AAOT) to sublingual allergen-specific immunotherapy (SASIT) for patients with allergic rhinitis (AR). A total of 120 eligible cases of adult patients with AR were included in this retrospective study. Of these, 60 patients received AAOT plus SASIT and were assigned to a treatment group, while

2019 Medicine

26. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy Full Text available with Trip Pro

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy.We (...) sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy.Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n = 20) or 25 μg of rMal d 1 (n = 20) or rBet v 1 (n = 20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick tests with recombinant

2017 EvidenceUpdates

27. [The analysis of Th2 cell subsets in house dust mite allergic rhinitis patients after sublingual immunotherapy]. (Abstract)

[The analysis of Th2 cell subsets in house dust mite allergic rhinitis patients after sublingual immunotherapy]. Th2 cells are well known to play important roles in allergic diseases including allergic rhinitis (AR). Meanwhile, the factors that induce and sustain the pathogenesis of AR remain unclear. The recent development of sublingual immunotherapy (SLIT) is expected to allow changes to the underlying pathogenesis of AR. However, the phenotype of the pathogenic Th2 cells (Tpath2) cells

2019 Nihon yakurigaku zasshi. Folia pharmacologica Japonica Controlled trial quality: uncertain

28. Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study. (Abstract)

Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study. Several foreign studies have shown long-term efficacy of sublingual immunotherapy (SLIT), but data on the long-term efficacy of SLIT in China are still lacking.We aimed to prospectively evaluate the long-term efficacy of a 2-year SLIT with Dermatophagoides farinae(D. farinae) drops in mono- and polysensitized children with allergic rhinitis (AR

2019 International Archives of Allergy and Immunology

29. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Full Text available with Trip Pro

Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Limited information is available regarding the current perception and practice of sublingual immunotherapy (SLIT) use among US and international allergists. In light of 4 recent US Food and Drug Administration (FDA)-approved SLIT options, perceptions and practices may be changing.To provide updated information about current allergists' practice and perception of SLIT (...) relative to 2007 and 2011.On behalf of the American College of Allergy, Asthma, and Immunology (ACAAI) Immunotherapy and Diagnostics Committee, an electronic survey was sent to all US and international allergists who were members of the ACAAI. Data were compared with previous surveys conducted and published in 2007 and 2011.Of the 305 respondents, 268 (87.9%) practiced in the United States. A total of 197 of 268 respondents (73.5%) reported experience using SLIT compared with 45 of 766 US allergists

2019 Asthma & Immunology

30. Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. Full Text available with Trip Pro

Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. To compare changes in quality of life (QOL) that resulted from sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) in a real-world clinical setting.SLIT is established as a viable alternative to SCIT for the treatment of allergic rhinitis. Although comparative trials are increasingly available, few studies have examined QOL outcomes (...) between these two treatments.One hundred and five participants who underwent immunotherapy for airborne allergies were enrolled in this prospective, single-center study. Forty participants completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation of therapy, after 6 months, and after 1 year of therapy. Only patients with complete time points were included in the ultimate analysis. Twenty-nine of these participants underwent SCIT and 11 underwent SLIT. The effects of age, sex

2017 American journal of rhinology & allergy

31. [Sublingual immunotherapy for respiratory allergies]

[Sublingual immunotherapy for respiratory allergies] L'immunothérapie sublinguale comme traitement des allergies respiratoires [Sublingual immunotherapy for respiratory allergies] L'immunothérapie sublinguale comme traitement des allergies respiratoires [Sublingual immunotherapy for respiratory allergies] Martin G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Martin G. L'immunothérapie sublinguale comme traitement des allergies respiratoires . [Sublingual immunotherapy for respiratory allergies] . Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Sublingual; Desensitization, Immunologic; Humans; Respiratory Hypersensitivity Language Published French Country of organisation Canada Province or state Quebec

2014 Health Technology Assessment (HTA) Database.

32. Prolonged effect of allergen sublingual immunotherapy to grass pollen. Full Text available with Trip Pro

Prolonged effect of allergen sublingual immunotherapy to grass pollen. The prolonged effect of allergen immunotherapy is unknown, especially in older patients.The three-year effect of sublingual allergen-specific immunotherapy (AIT) to grass pollen on elderly patients with allergic rhinitis was analyzed.Thirty-eight elderly patients (63.18 ± 3.12 yrs.) underwent AIT to grass pollen, were monitored for three years and were compared to a placebo group. AIT was performed with the use of an oral

2018 Human vaccines & immunotherapeutics Controlled trial quality: uncertain

33. Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. (Abstract)

Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. Prevalence of allergic diseases is increasing worldwide. Allergen-specific immunotherapy (ASIT) is potentially the only curative treatment for allergy, but there is a lack of reliable methods to monitor the immune responses to ASIT and to predict clinical efficacy. Recently, the definition of allergen sensitivity threshold (CD-Sens) by Basophil Activation Tests has been suggested as potential method (...) in this context. The aim of this study was to compare trends of CD-Sens, measured by the markers CD63 and CD203c, and clinical symptoms in subjects with allergic rhinitis receiving Sublingual Immunotherapy (SLIT). 26 rhinitis patients allergic to Parietaria were selected and matched into two groups; a SLIT treated group (SG) and a reference group (RG) treated by traditional anti-allergic medications. Visual Analogue Scale (VAS) score for the four cardinal symptoms of rhinitis and peripheral blood

2018 International immunopharmacology Controlled trial quality: uncertain

34. [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in children with allergic rhinitis and the change of TGF-β and IL-13 mRNA level]. (Abstract)

[Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in children with allergic rhinitis and the change of TGF-β and IL-13 mRNA level]. Objective:The aim of this study is to evaluate the efficacy of sublingual immunotherapy (SLIT) with standardized dermatophagoides farinae drops and to examine the change of TGF-β and IL-13 mRNA level after 12 months SLIT in children with allergic rhinitis (AR). Method:Ninety-two children with AR were collected and randomly divided into two (...) groups: SLIT group (n=62) and control group (n=30). Before and after SLIT for 6 months and 12 months, total nasal symptoms score (TNSS) and total medication score (TMS) were evaluated. In addition, the mRNA expression of TGF-β and IL-13 in peripheral blood mononuclear cells of AR children after immunotherapy were examined by qRT-PCR. Result:There were significant differences (P<0.01) in symptom and medication scores between the two groups after 12 months treatment. The patients in SLIT group had

2018 Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery Controlled trial quality: uncertain

35. Role of leptin in allergic rhinitis during sublingual immunotherapy. (Abstract)

Role of leptin in allergic rhinitis during sublingual immunotherapy. Increasing evidence suggests that leptin is upregulated during allergic reactions in the airway and related to the severity of disease in allergic rhinitis (AR). In this study, we aimed to investigate the expression of leptin during sublingual immunotherapy (SLIT) in AR patients.Forty AR patients without obesity were recruited in this study. Twenty patients received house dust mite (HDM) allergen extract for SLIT and twenty

2018 European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

36. Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet. (Abstract)

Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet. Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen sublingual immunotherapy (SLIT) tablet was developed using the highest concentration of JC pollen extract.This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected

2018 The journal of allergy and clinical immunology. In practice Controlled trial quality: predicted high

37. Sublingual dust mite immunotherapy for asthma. (Abstract)

Sublingual dust mite immunotherapy for asthma. 27174742 2018 03 21 2018 03 21 2213-2619 4 6 2016 06 The Lancet. Respiratory medicine Lancet Respir Med Sublingual dust mite immunotherapy for asthma. 436 10.1016/S2213-2600(16)30101-1 S2213-2600(16)30101-1 Harding Emilia E eng Comparative Study Multicenter Study News Randomized Controlled Trial 2016 05 09 England Lancet Respir Med 101605555 2213-2600 0 Antigens, Dermatophagoides IM Adult Animals Antigens, Dermatophagoides administration & dosage (...) Asthma diagnosis immunology therapy Double-Blind Method Female Humans Male Mites Prospective Studies Reference Values Severity of Illness Index Sublingual Immunotherapy methods Treatment Outcome United Kingdom 2016 5 14 6 0 2016 5 14 6 0 2018 3 22 6 0 ppublish 27174742 S2213-2600(16)30101-1 10.1016/S2213-2600(16)30101-1

2018 The lancet. Respiratory medicine Controlled trial quality: uncertain

38. Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy. (Abstract)

Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy. To compare immunologic modification and treatment outcomes after 2 years of sublingual immunotherapy (SLIT) with house dust mite extracts (HDM) between monosensitized and polysensitized patients with allergic rhinitis.Retrospective cohort study.Among the patients who were prospectively enrolled in the SLIT cohort study, patients with allergic rhinitis who were sensitized to HDM and treated with SLIT

2018 Laryngoscope

39. A birch sublingual allergy immunotherapy (SLIT) tablet educes rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG<sub>4</sub> to allergens from all trees in the birch homologous group. Full Text available with Trip Pro

A birch sublingual allergy immunotherapy (SLIT) tablet educes rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. This randomized, double-blind trial was conducted to determine the optimal dose for clinical efficacy of the SQ tree SLIT-tablet. An environmental exposure chamber (EEC) was used to reduce variability of allergen exposure and allow investigation of symptom reduction towards different

2018 Allergy Controlled trial quality: predicted high

40. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy Full Text available with Trip Pro

Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy Clinical practice needs a common parameter that can provide an early, reliable estimation of the outcome of sublingual immunotherapy (SLIT) in an upcoming pollen season. We investigated whether the conjunctival provocation test (CPT) can predict the beneficial outcome of SLIT in patients with allergic rhinoconjunctivitis after 4 weeks of treatment.We conducted two separate

2018 Clinical and translational allergy Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>